Exelixis Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Exelixis Contact Number

Contact Us Exelixis

6 hours ago Exelixis.com Show details

(650) 837-70001851 Harbor Bay Parkway Alameda, CA 94502 (650) 837-7000 phone (650) 837-8300 fax

Category: Contact SupportShow more

Exelixis Company Contact Information Email, Phone …

7 hours ago Adapt.io Show details

Get Exelixis company's verified contact number +1*****000, web address, revenue, total contacts 455, industry Healthcare, Pharmaceuticals, & Biotech and location at Adapt.io

Category: Phone Number, Contact SupportShow more

Exelixis, Inc. Company Profile Alameda, CA Competitors

6 hours ago Dnb.com Show details

(650) 837-7000Pharmaceutical and Medicine Manufacturing Chemical Manufacturing Manufacturing. Address: 1851 Harbor Bay Pkwy Alameda, CA, 94502-3010 United States See other locations. Phone: (650) 837-7000. Website: www.exelixis.com.

Employees: 57
Total Assets: $2,137
Tangible Fixed Assets: $67
Location: 1851 Harbor Bay Pkwy, Alameda, 94502-3010, CA

Category: Contact NumberShow more

Exelixis Crunchbase Company Profile & Funding

8 hours ago Crunchbase.com Show details

Phone Number 6508378300. Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the

Founder: Stelios Papadopoulos

Category: Contact NumberShow more

Exelixis Helping Patients Recover Stronger and Live Longer

5 hours ago Exelixis.com Show details

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for …

Category: Contact NumberShow more

Exelixis Access Services (EASE) offers access assistance

3 hours ago Cabometyxhcp.com Show details

12.29.235

1. Hemorrhage:Severe and fatal hemorrhages occurred with CABOMETYX. The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies. Discontinue CABOMETYX for Grade 3 or 4 hemorrhage. Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. Perforations and Fistulas:Fistulas, including fatal cases, occurred in 1% of CABOMETYX patients. Gastrointestinal (GI) perforations, including fatal cases, occurred in 1% of CABOMETYX patients. Monitor patients for signs and symptoms of fistulas and perforations, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a Grade 4 fistula or a GI perforation. Thrombotic Events:CABOMETYX increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events occurred in CABOMETYX patients. Discontinue CAB...

Category: Contact NumberShow more

Exelixis Company Profile Office Locations, Competitors

5 hours ago Craft.co Show details

Exelixis has 617 employees at their 1 location and $853.83 M in annual revenue in FY 2018. See insights on Exelixis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Contact NumberShow more

Study of Cabozantinib in Combination With Atezolizumab

7 hours ago Clinicaltrials.gov Show details

(888-393-5494You have reached the maximum number of saved studies (100). Contact: Exelixis Clinical Trials: 1-888-EXELIXIS (888-393-5494) [email protected]exelixis.com: Contact: Backup or International: 650-837-7400: Locations. Show 207 study locations Sponsors and Collaborators. Exelixis. Roche-Genentech

Category: Contact NumberShow more

Stekki Millman Director, Public Affairs, Exelixis

1 hours ago Winmo.com Show details

Verified contact information for Stekki Millman - Director, Public Affairs, Exelixis Pharmaceuticals, Inc. including email address, phone number and personality insights that will make your sales and marketing efforts much more effective.

Email: s*******@********.com
Location: 1851 Harbor Bay Parkway, Alameda, 94502, CA

Category: Contact NumberShow more

Exelixis, Inc. (EXEL) Company Profile & Facts Yahoo Finance

4 hours ago Finance.yahoo.com Show details

Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. Corporate Governance Exelixis, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 3.

Category: Contact NumberShow more

EXELIXIS LIFE SCIENCES PRIVATE LIMITED Company

4 hours ago Zaubacorp.com Show details

Exelixis Life Sciences Private Limited's Corporate Identification Number is (CIN) U33309BR2020PTC049262 and its registration number is 49262.Its Email address is [email protected] and its registered address is H/O-MEENA SINHA,CHITARAGUPTA NAGAR KANKERBAGH PATNA Patna BR 800020 IN , - , .

Category: Contact NumberShow more

Paige Mahaney Senior Vice President, D.. Exelixis

1 hours ago Zoominfo.com Show details

View Paige Mahaney's business profile as Senior Vice President, Discovery at Exelixis. Find contact's direct phone number, email address, work history, and more.

Category: Contact NumberShow more

What Type Of Shareholders Own The Most Number of Exelixis

1 hours ago News.yahoo.com Show details

Exelixis has a market capitalization of US$6.1b, so it's too big to fly under the radar. We'd expect to see both institutions and retail investors owning a portion of the company. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company.

Category: Contact NumberShow more

Exelixis Services Limited in Wilmington, DE Company Info

9 hours ago Bizapedia.com Show details

Exelixis Services Limited is a Delaware Corporation filed On August 6, 2003. The company's File Number is listed as 3689828. The Registered Agent on file for this company is American Incorporators Ltd. and is located at 1013 Centre Road Suite 403-A, Wilmington, DE 19805.

Location: DE

Category: Contact NumberShow more

Exelixis Announces Enrollment Completion in Phase 3

2 hours ago Finance.yahoo.com Show details

ALAMEDA, Calif., January 05, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy and safety of

Category: Contact NumberShow more

Hedge Funds Are Selling Exelixis, Inc. (EXEL)

8 hours ago Finance.yahoo.com Show details

Exelixis, Inc. (NASDAQ: EXEL) was in 30 hedge funds' portfolios at the end of September. The all time high for this statistic is 39. There were 33 hedge funds in our database with EXEL positions

1. Author: Asma UL Husna

Category: Contact NumberShow more

Exelixis Elects Jacqueline Wright to Its Board of

4 hours ago Citizentribune.com Show details

423-581-5630You will need the account number from your most recent print invoice. Call us at 423-581-5630 ext 366 if you do not have it. Exelixis Media Contact: Hal Mackins. For Exelixis, Inc. (415) 994

Category: Contact NumberShow more

Exelixis: Number of Employees 20062021 EXEL MacroTrends

5 hours ago Macrotrends.net Show details

Interactive chart of Exelixis (EXEL) annual worldwide employee count from 2006 to 2021. Exelixis total number of employees in 2020 was 773, a 25.28% increase from 2019. Exelixis total number of employees in 2019 was 617, a 27.48% increase from 2018. Exelixis total number of employees in 2018 was 484, a 30.11% increase from 2017.

Category: Contact NumberShow more

Exelixis Announces Preliminary Fourth Quarter and Full

1 hours ago Streetinsider.com Show details

Fourth Quarter 2021. Full Year 2021. Full Year 2022 Guidance. Net product revenues ~ $300 million ~ $1.08 billion $1.325 billion - $1.425 billion Cost of goods sold

Category: Contact NumberShow more

Contact Us – Excelleris

8 hours ago Excelleris.com Show details

604-658-2111Excelleris. 200-3500 Gilmore Way. Burnaby, BC V5C 2W7. Tel: 604-658-2111 (Monday to Friday 8:00am – 4:00pm PST) Fax: 604-291-6837. [email protected] For members of the media seeking more information about Excelleris, please email our parent company LifeLabs at: [email protected]

Category: Cell Phone, Contact SupportShow more

Nina Krifuks Senior Clinical Trials Ma.. Exelixis

Just Now Zoominfo.com Show details

View Nina Krifuks's business profile as Senior Clinical Trials Manager at Exelixis. Find contact's direct phone number, email address, work history, and more.

Category: Contact NumberShow more

Exelixis Announces Preliminary Fourth Quarter and Full

4 hours ago Ca.finance.yahoo.com Show details

"As we enter 2022, Exelixis is on a clear path to becoming a multi-product oncology company. Fueled by the commercial success of CABOMETYX, we are rapidly advancing our expanding portfolio of differentiated therapeutic candidates with the potential to improve outcomes for a growing number of patients with cancer," said Michael M. Morrissey, …

Category: Contact NumberShow more

Exelixis Announces Enrollment Completion in Phase 3

6 hours ago Marketscreener.com Show details

Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy and safety of cabozantinib (CABOMETYX ®) in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal …

Category: Contact NumberShow more

Exelixis and Iconic Therapeutics Amend Option and License

5 hours ago Pipelinereview.com Show details

Under the amended agreement announced today, Exelixis has acquired broad rights to use the anti-TF antibody incorporated into XB002, for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multi-specific biologics.

Category: Contact NumberShow more

Exelixis Announces Enrollment Completion in Phase 3

7 hours ago Us.acrofan.com Show details

CONTACT-03 is one of three pivotal trials that are part of an ongoing clinical collaboration with Roche –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy and safety of cabozantinib (CABOMETYX®) in combination with …

Category: Contact NumberShow more

Exelixis Announces Preliminary Fourth Quarter and Full

8 hours ago Joplinglobe.com Show details

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan 9, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2021, provided

Category: Contact NumberShow more

Analysts Anticipate Exelixis, Inc. (NASDAQ:EXEL) Will

1 hours ago Marketbeat.com Show details

A number of brokerages recently issued reports on EXEL. HC Wainwright dropped their target price on shares of Exelixis from $65.00 to $52.00 and set a "buy" rating on the stock in a research report on Wednesday, November 3rd. Piper Sandler initiated coverage on shares of Exelixis in a report on Friday, November 19th.

Category: Contact NumberShow more

Hedge Funds Are Selling Exelixis, Inc. (EXEL) Insider Monkey

5 hours ago Insidermonkey.com Show details

Exelixis, Inc. (NASDAQ: EXEL) was in 30 hedge funds’ portfolios at the end of September. The all time high for this statistic is 39. There were 33 hedge funds in our database with EXEL positions

Category: Contact NumberShow more

Exelixis and Iconic Therapeutics Amend Option and License

1 hours ago Biospace.com Show details

650-837-7917Exelixis Investor Contact: Varant Shirvanian Senior Investor Relations Manager Exelixis, Inc. 650-837-7917 [email protected]exelixis.com Exelixis Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 [email protected] Iconic Media and Investor Contact: Shari Annes (650) 888-0902 [email protected]

Category: Contact NumberShow more

EXELIXIS, INC. : Shareholders Board Members Managers and

9 hours ago Marketscreener.com Show details

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options.

Category: Contact NumberShow more

The RAxML v8.2.X Manual

2 hours ago Cme.h-its.org Show details

more threads/cores you can use efficiently. Also note that, efficiency varies depending on the type of data, or more precisely, the number of states in your data (e.g., 4 in DNA, 20 for proteins).

Category: Contact NumberShow more

Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid

1 hours ago Finance.yahoo.com Show details

Exelixis, Inc. EXEL recently announced that it has initiated the dose-escalation stage of its phase Ib study, STELLAR-002. STELLAR-002 is the second study to evaluate XL092 in advanced cancers

Category: Contact NumberShow more

Peter Lamb Sells 47,500 Shares of Exelixis, Inc. (NASDAQ

3 hours ago Marketbeat.com Show details

A number of research analysts have issued reports on EXEL shares. Oppenheimer lowered their price objective on Exelixis from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Tuesday, November 2nd.

Category: Contact NumberShow more

Current Report Filing (8k)

Just Now Ih.advfn.com Show details

(650) 837-70001851 Harbor Bay Parkway. Alameda, California 94502. (Address of principal executive offices) (Zip Code) (650) 837-7000. (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

Category: Contact NumberShow more

Exelixis Wikipedia

8 hours ago En.wikipedia.org Show details

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. History. Exelixis was founded in 1994; the scientific founders were Spyridon …

Category: Contact NumberShow more

EXEL Stock quote for EXELIXIS, INC. MSN Money

3 hours ago Msn.com Show details

Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by State of New Jersey Common Pension Fund D ETF Daily News 12/23/2021 What Type Of Shareholders Own The Most Number of Exelixis, Inc. (NASDAQ:EXEL) Shares?

Category: Contact NumberShow more

Exelixis Announces Second Quarter 2021 Financial Results

4 hours ago Finance.yahoo.com Show details

ALAMEDA, Calif., August 05, 2021--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2021 and provided an update on progress toward achieving key corporate

Category: Contact NumberShow more

Joseph Miller Oncology Market Development Exelixis

7 hours ago Apollo.io Show details

(650) 837-7000Joseph Miller's Professional Contact Details. Email (Verified) j**@exelixis.com. Get Email Address. Headquarter. (650) 837-7000. Location. Flagstaff, Arizona.

Category: Contact NumberShow more

EXEL Graham Number Exelixis GuruFocus.com

5 hours ago Gurufocus.com Show details

EXEL Graham Number as of today (January 12, 2022) is $8.66. In depth view into Exelixis Graham Number explanation, calculation, historical data and more

Category: Contact NumberShow more

Cornercap Group Of Funds Buys Alpha Metallurgical

8 hours ago Finance.yahoo.com Show details

Cornercap Group Of Funds initiated holding in Exelixis Inc. The purchase prices were between $16.3 and $21.14, with an estimated average price of …

Category: Contact NumberShow more

A Peek Into The Markets: US Stock Futures Edge Higher

8 hours ago Markets.businessinsider.com Show details

Oil prices traded higher as Brent crude futures rose 0.5% to trade at $82.13 per barrel, while US WTI crude futures gained 0.5% to trade at $79.29 a barrel. The total number of active U.S. oil

Category: Contact NumberShow more

Exelixis Announces Preliminary Fourth Quarter and Full

3 hours ago Benzinga.com Show details

Exelixis, Inc. (NASDAQ:EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2021, provided financial guidance for full year 2022, and delivered an

Category: Contact NumberShow more

Here's Why Exelixis Stock Is Dropping Today The Motley Fool

5 hours ago Fool.com Show details

This year, Exelixis expects sales and royalties from cabozantinib to reach between $1.15 billion and $1.25 billion. At the midpoint, that's 22% more than the company reported in 2020.

Category: Contact NumberShow more

What is Exelixis Valuation? EXEL Macroaxis

9 hours ago Macroaxis.com Show details

Exelixis shows a prevailing Real Value of $22.22 per share. The current price of the firm is $19.28. At this time, the firm appears to be undervalued.Our model computes the value of Exelixis from reviewing the firm fundamentals such as Shares Outstanding of 313.39 M, profit margin of 8.13 %, and Current Valuation of 5.21 B as well as analyzing its technical indicators …

Category: Contact NumberShow more

Exelixis hiring Associate Corporate Counsel, Contracts in

5 hours ago Linkedin.com Show details

Exelixis is seeking an Associate Corporate Counsel, Contracts to join the Legal Department’s contracting team, reporting to the Executive Director, Legal Affairs and Senior Corporate Counsel.

Category: Contact NumberShow more

Exelixis Inc (EXEL) Részvényárfolyamtörténet wallmine

5 hours ago Hu.wallmine.com Show details

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the …

Category: Contact NumberShow more

Earnings Preview: Exelixis (EXEL) Q4 Earnings Expected to

8 hours ago Nasdaq.com Show details

021-02-03Feb 3, 2021 12:31PM EST. W all Street expects a year-over-year decline in earnings on higher revenues when Exelixis (EXEL) reports results for the quarter ended December 2020. While this widely

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What is Exelixis Inc (Exel)?

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

Who are the executives of Exelixis?

Exelixis's key executives are Michael M. Morrissey, Stelios Papadopoulos and Charles Cohen. How many employees does Exelixis have? Exelixis has 617 employees. What is Exelixis revenue? Latest Exelixis annual revenue is $853.8 m. What is Exelixis revenue per employee? Latest Exelixis revenue per employee is $1.4 m. Who are Exelixis competitors?

Where is the headquarters of Exelixis located?

Exelixis headquarters is located at 1851 Harbor Bay Pkwy, Alameda. Where are Exelixis offices? Exelixis has an office in Alameda. How many offices does Exelixis have? Exelixis has 1 office.

Does Exelixis provide medical or legal advice?

Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed health care provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.

Popular Brands

Essity
Engie
Eaton